Distinct Binding and Immunogenic Properties of the Gonococcal Homologue of Meningococcal Factor H Binding Protein

Neisseria meningitidis is a leading cause of sepsis and meningitis. The bacterium recruits factor H (fH), a negative regulator of the complement system, to its surface via fH binding protein (fHbp), providing a mechanism to avoid complement-mediated killing. fHbp is an important antigen that elicits protective immunity against the meningococcus and has been divided into three different variant groups, V1, V2 and V3, or families A and B. However, immunisation with fHbp V1 does not result in cross-protection against V2 and V3 and vice versa. Furthermore, high affinity binding of fH could impair immune responses against fHbp. Here, we investigate a homologue of fHbp in Neisseria gonorrhoeae, designated as Gonococcal homologue of fHbp (Ghfp) which we show is a promising vaccine candidate for N. meningitidis. We demonstrate that Gfhp is not expressed on the surface of the gonococcus and, despite its high level of identity with fHbp, does not bind fH. Substitution of only two amino acids in Ghfp is sufficient to confer fH binding, while the corresponding residues in V3 fHbp are essential for high affinity fH binding. Furthermore, immune responses against Ghfp recognise V1, V2 and V3 fHbps expressed by a range of clinical isolates, and have serum bactericidal activity against N. meningitidis expressing fHbps from all variant groups.

[1]  R. Rappuoli,et al.  The factor H binding protein of Neisseria meningitidis interacts with xenosiderophores in vitro. , 2012, Biochemistry.

[2]  Steven W. Johnson,et al.  Design and Evaluation of Meningococcal Vaccines through Structure-Based Modification of Host and Pathogen Molecules , 2012, PLoS pathogens.

[3]  R. Rappuoli,et al.  Novel meningococcal 4CMenB vaccine antigens – prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae , 2012, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[4]  John L. Perez,et al.  Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. , 2012, The Lancet. Infectious diseases.

[5]  M. Valenzuela,et al.  Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study , 2012, The Lancet.

[6]  Ly-Mee Yu,et al.  Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. , 2012, JAMA.

[7]  R. Rappuoli,et al.  Rational Design of a Meningococcal Antigen Inducing Broad Protective Immunity , 2011, Science Translational Medicine.

[8]  S. Ram,et al.  Molecular Characterization of the Interaction between Sialylated Neisseria gonorrhoeae and Factor H* , 2011, The Journal of Biological Chemistry.

[9]  R. Exley,et al.  Characterization of Neisseria meningitidis Isolates That Do Not Express the Virulence Factor and Vaccine Antigen Factor H Binding Protein , 2011, Clinical and Vaccine Immunology.

[10]  S. Ram,et al.  A Meningococcal Factor H Binding Protein Mutant That Eliminates Factor H Binding Enhances Protective Antibody Responses to Vaccination , 2011, The Journal of Immunology.

[11]  R. Rappuoli,et al.  Characterization of Diverse Subvariants of the Meningococcal Factor H (fH) Binding Protein for Their Ability To Bind fH, To Mediate Serum Resistance, and To Induce Bactericidal Antibodies , 2010, Infection and Immunity.

[12]  S. Ram,et al.  The Meningococcal Vaccine Candidate Neisserial Surface Protein A (NspA) Binds to Factor H and Enhances Meningococcal Resistance to Complement , 2010, PLoS pathogens.

[13]  O. Kurzai,et al.  Virulence determinants involved in differential host niche adaptation of Neisseriameningitidis and Neisseria gonorrhoeae , 2010, Medical Microbiology and Immunology.

[14]  M. Pizza,et al.  Characterization of fHbp, nhba (gna2132), nadA, porA, and Sequence Type in Group B Meningococcal Case Isolates Collected in England and Wales during January 2008 and Potential Coverage of an Investigational Group B Meningococcal Vaccine , 2010, Clinical and Vaccine Immunology.

[15]  D. Granoff,et al.  The modular architecture of meningococcal factor H-binding protein. , 2009, Microbiology.

[16]  P. Roversi,et al.  Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates , 2009, Nature.

[17]  S. Ram,et al.  Factor H and neisserial pathogenesis. , 2008, Vaccine.

[18]  R. Rappuoli,et al.  Factor H-Binding Protein Is Important for Meningococcal Survival in Human Whole Blood and Serum and in the Presence of the Antimicrobial Peptide LL-37 , 2008, Infection and Immunity.

[19]  D. Granoff,et al.  Bactericidal Antibody Responses Induced by Meningococcal Recombinant Chimeric Factor H-Binding Protein Vaccines , 2008, Infection and Immunity.

[20]  B. Greenwood,et al.  Epidemic meningitis, meningococcaemia, and Neisseria meningitidis , 2007, The Lancet.

[21]  S. Ram,et al.  Interactions between Neisseria meningitidis and the complement system. , 2007, Trends in microbiology.

[22]  I. Aaberge,et al.  Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. , 2007, Vaccine.

[23]  S. Ram,et al.  Factor H Binding and Function in Sialylated Pathogenic Neisseriae is Influenced by Gonococcal, but Not Meningococcal, Porin1 , 2007, The Journal of Immunology.

[24]  M. Ramsay,et al.  Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. , 2007, FEMS microbiology reviews.

[25]  R. Rappuoli,et al.  A universal vaccine for serogroup B meningococcus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  David H Perlman,et al.  The Meningococcal Vaccine Candidate GNA1870 Binds the Complement Regulatory Protein Factor H and Enhances Serum Resistance , 2006, The Journal of Immunology.

[27]  Robert B Sim,et al.  Functional Significance of Factor H Binding to Neisseria meningitidis1 , 2006, The Journal of Immunology.

[28]  N. West,et al.  Available carbon source influences the resistance of Neisseria meningitidis against complement , 2005, The Journal of experimental medicine.

[29]  D. Caugant,et al.  Neisseria meningitidis: an overview of the carriage state. , 2004, Journal of medical microbiology.

[30]  M. Carroll,et al.  The complement system in B cell regulation. , 2004, Molecular immunology.

[31]  Ying Zhang,et al.  Vaccine Potential of the Neisseria meningitidis 2086 Lipoprotein , 2004, Infection and Immunity.

[32]  C. Hart,et al.  Meningococcal Disease , 1974, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[33]  Jeannette Adu-Bobie,et al.  Vaccination against Neisseria meningitidis Using Three Variants of the Lipoprotein GNA1870 , 2003, The Journal of experimental medicine.

[34]  S. Seal,et al.  The Neisseria Lipooligosaccharide-Specific α-2,3-Sialyltransferase Is a Surface-Exposed Outer Membrane Protein , 2002, Infection and Immunity.

[35]  G. Remuzzi,et al.  Factor H family proteins: on complement, microbes and human diseases. , 2001, Biochemical Society transactions.

[36]  A. Blom,et al.  C4bp binding to porin mediates stable serum resistance of Neisseria gonorrhoeae. , 2001, International immunopharmacology.

[37]  A. Blom,et al.  Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of Neisseria gonorrhoeae , 2001 .

[38]  J. V. D. van der Meer,et al.  Update on meningococcal disease with emphasis on pathogenesis and clinical management. , 2000, Clinical microbiology reviews.

[39]  M. Frosch,et al.  Mechanisms of neisserial serum resistance , 1999, Molecular microbiology.

[40]  D. Stephens,et al.  The (α2→8)-Linked Polysialic Acid Capsule and Lipooligosaccharide Structure Both Contribute to the Ability of Serogroup B Neisseria meningitidis To Resist the Bactericidal Activity of Normal Human Serum , 1998, Infection and Immunity.

[41]  H. Seifert,et al.  Differential roles of homologous recombination pathways in Neisseria gonorrhoeae pilin antigenic variation, DNA transformation and DNA repair , 1998, Molecular microbiology.

[42]  S. Ram,et al.  Binding of Complement Factor H to Loop 5 of Porin Protein 1A: A Molecular Mechanism of Serum Resistance of Nonsialylated Neisseria gonorrhoeae , 1998, The Journal of experimental medicine.

[43]  G. Carlone,et al.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group , 1997, Clinical and diagnostic laboratory immunology.

[44]  G. Carlone,et al.  Standardization and a Multilaboratory Comparison ofNeisseria meningitidisSerogroup A and C Serum Bactericidal Assays , 1997 .

[45]  J. Cole,et al.  Serum killing of meningococci and several other gram-negative bacterial species is not decreased by incubating them with cytidine 5'-monophospho-N-acetyl neuraminic acid. , 1989, Microbial pathogenesis.

[46]  J. Cole,et al.  Cytidine 5'-monophospho-N-acetylneuraminic acid or a related compound is the low Mr factor from human red blood cells which induces gonococcal resistance to killing by human serum. , 1988, Journal of general microbiology.

[47]  M. Leinonen,et al.  ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITIS Implications for Vaccine Development and Pathogenesis , 1983, The Lancet.

[48]  C. Cordova,et al.  TYPE-III HYPERUPOPROTEINÆMIA , 1977, The Lancet.